Does the media refer more to LONA or SLGL?

In the previous week, Athira Pharma had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 7 mentions for Athira Pharma and 4 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.80 beat Athira Pharma's score of 0.73 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SBTX or LONA?

Athira Pharma has a consensus price target of $16.00, suggesting a potential upside of 100.50%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings and valuation, SBTX or LONA?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Athira Pharma N/A N/A -$105.61M -$5.21 N/A

Is SBTX or LONA more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Athira Pharma N/A -381.01% -225.74%

Which has stronger earnings & valuation, LONA or NERV?

Athira Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A

Is LONA or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Minerva Neurosciences N/A N/A -31.72%

Does the media refer more to LONA or NERV?

In the previous week, Minerva Neurosciences had 12 more articles in the media than Athira Pharma. MarketBeat recorded 19 mentions for Minerva Neurosciences and 7 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.73 beat Minerva Neurosciences' score of 0.19 indicating that Athira Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, ANTX or LONA?

Anthem is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Athira Pharma N/A N/A -$105.61M -$5.21 N/A

Is ANTX or LONA more profitable?

Anthem's return on equity of -53.52% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Athira Pharma N/A -381.01% -225.74%

Do analysts rate SIGA or LONA?

Athira Pharma has a consensus price target of $16.00, indicating a potential upside of 100.50%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Athira Pharma (LONA) Competitors

$7.98 +0.11 (+1.40%)

Closing price 03:58 PM Eastern

Extended Trading

$7.97 -0.01 (-0.08%)

As of 07:58 PM Eastern

Compare

LONA vs. SLGL, SBTX, NERV, ANTX, and SIGA

Should you buy Athira Pharma stock or one of its competitors? Athira Pharma's main competitors and comparable companies include Sol-Gel Technologies (SLGL), Silverback Therapeutics (SBTX), Minerva Neurosciences (NERV), Anthem (ANTX), and Siga Technologies (SIGA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athira Pharma compare to Sol-Gel Technologies?

Athira Pharma (NASDAQ:LONA) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Athira Pharma had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 7 mentions for Athira Pharma and 4 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.80 beat Athira Pharma's score of 0.73 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sol-Gel Technologies has higher revenue and earnings than Athira Pharma. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Sol-Gel Technologies	$19.39M	12.27	-$6.13M	-$0.34	N/A

Athira Pharma has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Athira Pharma presently has a consensus target price of $16.00, suggesting a potential upside of 100.50%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 133.20%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Athira Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Summary

Sol-Gel Technologies beats Athira Pharma on 10 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Silverback Therapeutics' return on equity of -29.62% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Athira Pharma	N/A	-381.01%	-225.74%

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Athira Pharma has a consensus price target of $16.00, suggesting a potential upside of 100.50%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Athira Pharma had 7 more articles in the media than Silverback Therapeutics. MarketBeat recorded 7 mentions for Athira Pharma and 0 mentions for Silverback Therapeutics. Athira Pharma's average media sentiment score of 0.73 beat Silverback Therapeutics' score of 0.00 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Athira Pharma	Positive

Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Summary

Silverback Therapeutics and Athira Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Minerva Neurosciences?

Athira Pharma (NASDAQ:LONA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Athira Pharma currently has a consensus target price of $16.00, indicating a potential upside of 100.50%. Minerva Neurosciences has a consensus target price of $10.33, indicating a potential upside of 125.62%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Athira Pharma has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

In the previous week, Minerva Neurosciences had 12 more articles in the media than Athira Pharma. MarketBeat recorded 19 mentions for Minerva Neurosciences and 7 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.73 beat Minerva Neurosciences' score of 0.19 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Athira Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Minerva Neurosciences' return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Minerva Neurosciences	N/A	N/A	-31.72%

Summary

Athira Pharma beats Minerva Neurosciences on 8 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Anthem?

Anthem (NASDAQ:ANTX) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

90.5% of Anthem shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 22.6% of Anthem shares are owned by insiders. Comparatively, 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 50.25%. Athira Pharma has a consensus price target of $16.00, suggesting a potential upside of 100.50%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Anthem's return on equity of -53.52% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Athira Pharma	N/A	-381.01%	-225.74%

Anthem has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

In the previous week, Athira Pharma had 5 more articles in the media than Anthem. MarketBeat recorded 7 mentions for Athira Pharma and 2 mentions for Anthem. Anthem's average media sentiment score of 1.48 beat Athira Pharma's score of 0.73 indicating that Anthem is being referred to more favorably in the media.

Company	Overall Sentiment
Anthem	Positive
Athira Pharma	Positive

Anthem is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Summary

Anthem and Athira Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Athira Pharma has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Siga Technologies' return on equity of -1.55% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Athira Pharma	N/A	-381.01%	-225.74%

In the previous week, Athira Pharma had 6 more articles in the media than Siga Technologies. MarketBeat recorded 7 mentions for Athira Pharma and 1 mentions for Siga Technologies. Athira Pharma's average media sentiment score of 0.73 beat Siga Technologies' score of 0.63 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Siga Technologies	Positive
Athira Pharma	Positive

Siga Technologies has higher revenue and earnings than Athira Pharma. Siga Technologies is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.28	$23.28M	-$0.05	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Athira Pharma has a consensus price target of $16.00, indicating a potential upside of 100.50%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Siga Technologies has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Athira Pharma beats Siga Technologies on 9 of the 14 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$73.93M	$11.73B	$6.98B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	N/A	781.47	269.86	25.30
Price / Sales	N/A	750.79	601.81	101.06
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	2.68	10.81	13.08	6.33
Net Income	-$105.61M	$2.77B	$3.45B	$347.70M
7 Day Performance	3.91%	0.17%	1.12%	1.07%
1 Month Performance	-16.18%	0.35%	1.79%	1.03%
1 Year Performance	N/A	161.52%	67.69%	20.77%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	3.8009 of 5 stars	$7.98 +1.4%	$16.00 +100.5%	N/A	$73.93M	N/A	N/A	40	News Coverage Earnings Report
SLGL Sol-Gel Technologies	3.9059 of 5 stars	$77.92 -8.0%	$197.50 +153.5%	+443.9%	$238.11M	$19.39M	N/A	50	News Coverage Upcoming Earnings
SBTX Silverback Therapeutics	N/A	$6.16 +11.0%	N/A	-63.7%	$222.12M	N/A	N/A	83	High Trading Volume
NERV Minerva Neurosciences	1.8285 of 5 stars	$4.32 -6.5%	$10.50 +143.1%	+116.6%	$220.59M	N/A	N/A	9	News Coverage Earnings Report Analyst Downgrade Analyst Revision Gap Up
ANTX Anthem	2.5243 of 5 stars	$5.87 -0.7%	$9.00 +53.3%	+458.9%	$212.85M	N/A	N/A	N/A	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. SLGL, SBTX, NERV, ANTX, and SIGA

How does Athira Pharma compare to Sol-Gel Technologies?

Summary

How does Athira Pharma compare to Silverback Therapeutics?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Summary

How does Athira Pharma compare to Anthem?

Summary

How does Athira Pharma compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. SLGL, SBTX, NERV, ANTX, and SIGA

How does Athira Pharma compare to Sol-Gel Technologies?

Does the media refer more to LONA or SLGL?

Do insiders & institutionals hold more shares of LONA or SLGL?

Which has higher earnings and valuation, LONA or SLGL?

Which has more risk and volatility, LONA or SLGL?

Do analysts prefer LONA or SLGL?

Is LONA or SLGL more profitable?

Summary

How does Athira Pharma compare to Silverback Therapeutics?

Is SBTX or LONA more profitable?

Do insiders and institutionals have more ownership in SBTX or LONA?

Do analysts prefer SBTX or LONA?

Does the media favor SBTX or LONA?

Which has more risk & volatility, SBTX or LONA?

Which has better earnings and valuation, SBTX or LONA?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Do analysts recommend LONA or NERV?

Which has more risk & volatility, LONA or NERV?

Does the media refer more to LONA or NERV?

Which has stronger earnings & valuation, LONA or NERV?

Do insiders & institutionals believe in LONA or NERV?

Is LONA or NERV more profitable?

Summary

How does Athira Pharma compare to Anthem?

Do insiders and institutionals have more ownership in ANTX or LONA?

Do analysts rate ANTX or LONA?

Is ANTX or LONA more profitable?

Which has more volatility and risk, ANTX or LONA?

Does the media prefer ANTX or LONA?

Which has higher earnings & valuation, ANTX or LONA?

Summary

How does Athira Pharma compare to Siga Technologies?

Is SIGA or LONA more profitable?

Does the media prefer SIGA or LONA?

Which has stronger valuation and earnings, SIGA or LONA?

Do analysts rate SIGA or LONA?

Which has more volatility & risk, SIGA or LONA?

Do insiders & institutionals hold more shares of SIGA or LONA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools